DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers

Information source: Emory University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hemophilia A

Intervention: Desmopressin (Drug)

Phase: Phase 1

Status: Enrolling by invitation

Sponsored by: Emory University

Official(s) and/or principal investigator(s):
Robert Sidonio, Jr., MD, Principal Investigator, Affiliation: Emory University

Summary

The purpose of this study is to determine how female hemophilia A carriers respond to a medication called DDAVP (Desmopressin).

Clinical Details

Official title: Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers

Study design: Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Primary outcome: Percentage of subjects that achieve and sustain >50% increase in Factor VIII antigen levels

Secondary outcome:

Change in the time-course response of Factor VIII antigen levels

Change in the time-course response of von Willebrand factor antigen (vWF:Ag) levels

Mean FVIII:C/vWF:Ag ratio in subjects with the baseline FVIII:C/vWF:Ag ratio of 1

Mean FVIII:C/vWF:Ag ratio in subjects with the baseline FVIII:C/vWF:Ag ratio of <1

Mean FVIII:C/vWF:Ag ratio in subjects with the baseline FVIII:C/vWF:Ag ratio of >1

Detailed description: DDAVP (Desmopressin) is commonly used in the treatment of persons with bleeding disorders such as hemophilia, von Willebrand disease, or qualitative platelet disorders to help them clot better. The investigator wants to assess the increase in the subjects' clotting factors in response to intravenous DDAVP (Desmopressin) and the levels of these internal clotting factors will be measured at different times after the medication is given. The investigator will compare the response to DDAVP (Desmopressin) in adult hemophilia A carriers to women with a diagnosis of qualitative platelet dysfunction.

Eligibility

Minimum age: 18 Years. Maximum age: 60 Years. Gender(s): Female.

Criteria:

Inclusion Criteria: Inclusion criteria for hemophilia A carriers:

- Females 18-60 years of age at time of enrollment

- Genetically verified or obligate hemophilia A carrier (mother of 2 boys with

hemophilia A, daughter of a father with hemophilia A or mother of a son and another male relative with hemophilia A)

- To stratify patients by carriage of mutation type 10 hemophilia carriers of mild

mutations that are predicted to lead to reduced FVIII secretion, protein stability or thrombin cleavage site interference and 10 hemophilia carriers of severe mutations that lead to predicted negative cross reactive material will be selected. Predicted FVIII function of the mutation will be verified by EAHAD (European Association for Haemophilia and Allied Disorders) Coagulant Factor Variant Database at www. eahad-db. org)

- Weight >40kg to ensure volumes of blood to be drawn are within accepted safe range

Inclusion criteria for non-hemophilia A carriers (Females with mild qualitative platelet dysfunction):

- Females 18-60 years of age at time of enrollment

- Whole blood or platelet rich plasma lumiaggregometry consistent with reduced

aggregation to at least 1 agonist on at least one occasion (excluding evidence of Glanzmanns Thrombasthenia or Bernard Soulier Syndrome) or determined by primary hematologist as having a qualitative platelet disorder

- Age-matched by 10 years to carrier enrolled

- Weight >40kg to ensure volumes of blood to be drawn are within accepted safe range

Exclusion Criteria:

- Personal history of concomitant bleeding or clotting disorder

- Cardiac condition that requires the daily use of Aspirin or Clopidogrel

- Inability to comply with fluid restriction protocol for 24 hours following

Desmopressin (DDAVP)

- Personal history of a myocardial infarction, renal or hepatic insufficiency or

epilepsy

Locations and Contacts

Children's Hospital of Atlanta Egleston, Atlanta, Georgia 30322, United States

Emory University, Atlanta, Georgia 30322, United States

Additional Information

Starting date: July 2015
Last updated: July 21, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017